Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ATHERSYS, INC / NEWATHX · Entity 95922 | Director | January 09, 2023 | January 11, 2023 |
| Acorda Therapeutics, Inc.ACOR · Entity 111987 | President, Intl and GC | December 02, 2019 | December 04, 2019 |
| RIGEL PHARMACEUTICALS INCRIGL · Entity 2423 | Director | May 15, 2026 | May 20, 2026 |
| SELLAS Life Sciences Group, Inc.SLS · Entity 4313 | Director | January 07, 2026 | January 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ATHERSYS, INC / NEW
Report date January 09, 2023 · Filed January 11, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,141 |
Reported balance
After 2023-01-09 transaction · row 1
1 source rowRow 1 · 2023-01-09 · Grant · Acquired 22,321 · Balance 35,141 F1: Represents the exempt acquisition of 22,321 restricted stock units that in general will vest in total on June 30, 2023, subject generally to the Reporting Person's continued service on the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the exempt acquisition of 22,321 restricted stock units that in general will vest in total on June 30, 2023, subject generally to the Reporting Person's continued service on the Issuer's Board of Directors.
Acorda Therapeutics, Inc.
Report date December 02, 2019 · Filed December 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 117,420 |
Reported balance
After 2019-12-02 transaction · row 1
1 source rowRow 1 · 2019-12-02 · Sale · Disposed 2,227 · Balance 117,420 F1: Sales pursuant to a 10b5-1 plan. These sales are primarily intended to cover the tax liability resulting from restricted stock vesting. F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $1.53 to $1.68 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: Sales pursuant to a 10b5-1 plan. These sales are primarily intended to cover the tax liability resulting from restricted stock vesting.
F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $1.53 to $1.68 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
RIGEL PHARMACEUTICALS INC
Report date May 15, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,250 |
Reported balance
After 2026-05-15 transaction · row 1
1 source rowRow 1 · 2026-05-15 · Grant · Acquired 5,750 · Balance 18,250 F1: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.
SELLAS Life Sciences Group, Inc.
Report date January 07, 2026 · Filed January 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 92,900 |
Reported balance
After 2026-01-07 transaction · row 1
1 source rowRow 1 · 2026-01-07 · Grant · Acquired 50,000 · Balance 92,900 F1: The Reporting Person received an award of 50,000 restricted stock units on January 7, 2026, which shall vest in full on December 1, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person received an award of 50,000 restricted stock units on January 7, 2026, which shall vest in full on December 1, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 19, 2018 Filed Jan 23, 2018 07:52 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 34,170 | $27.58 | $942,299.26 |
DisclosureSEC source: 0001209191-18-004824 · doc4.xml · nonDerivative · entry 2 Wasman Jane · CIK 0001352455 · President, Intl and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,460 F1 · shares: Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2018 on the expiration date reported within Table II unless exercised. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $27.10 to $28.00 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 07:52 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Exercise / conversionCommon Stock | 34,520 | $19.81 | $683,841.20 |
DisclosureSEC source: 0001209191-18-004824 · doc4.xml · nonDerivative · entry 1 Wasman Jane · CIK 0001352455 · President, Intl and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,630 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2018 on the expiration date reported within Table II unless exercised. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 07:46 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 4,564 | $20.52 | $93,662.41 |
DisclosureSEC source: 0001209191-17-063699 · doc4.xml · nonDerivative · entry 1 Wasman Jane · CIK 0001352455 · President, Intl and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,110 F1 · shares: Sales pursuant to a 10b5-1 plan. These sales are primarily intended to cover the tax liability resulting from equity vesting. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $20.10 to $20.90 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 16:38 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantEmployee Stock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $27.48 | $0.00 |
DisclosureSEC source: 0001209191-17-017623 · doc4.xml · derivative · entry 2 Wasman Jane · CIK 0001352455 · President, Intl and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2027-03-01 F2 · derivative.exercise_date: The shares subject to this option vest in equal quarterly installments over four years beginning on January 1, 2017 with the first quarterly installment vesting on April 1, 2017. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 16:38 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-017623 · doc4.xml · nonDerivative · entry 1 Wasman Jane · CIK 0001352455 · President, Intl and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,674 F1 · shares: Restricted shares issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares will vest 25% every year for four years with vest dates of December 1, 2017, December 1, 2018, December 1, 2019 and December 1, 2020. Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 16:16 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 54,536 | $0.00 Strike: $22.13 | $0.00 |
DisclosureSEC source: 0001209191-17-009976 · doc4.xml · derivative · entry 3 Wasman Jane · CIK 0001352455 · President, Intl and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 54,536 shares Expires 2017-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2017 on the expiration date reported within Table II unless exercised. F3 · derivative.exercise_date: The shares subject to these options vested in installments and were fully vested on 10/01/2010. Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 16:16 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 54,536 | $22.30 | $1,216,218.24 |
DisclosureSEC source: 0001209191-17-009976 · doc4.xml · nonDerivative · entry 2 Wasman Jane · CIK 0001352455 · President, Intl and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,674 F1 · shares: Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2017 on the expiration date reported within Table II unless exercised. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $22.25 to $22.95 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 16:16 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Exercise / conversionCommon Stock | 54,536 | $22.13 | $1,206,881.68 |
DisclosureSEC source: 0001209191-17-009976 · doc4.xml · nonDerivative · entry 1 Wasman Jane · CIK 0001352455 · President, Intl and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2017 on the expiration date reported within Table II unless exercised. Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 17:15 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 100 | $21.30 | $2,130.00 |
DisclosureSEC source: 0001209191-16-153415 · doc4.xml · nonDerivative · entry 2 Wasman Jane · CIK 0001352455 · President, Intl and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,674 F1 · shares: Sales pursuant to a 10b5-1 plan. These sales are primarily intended to cover the tax liability resulting from restricted stock vesting. Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 17:15 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 3,247 | $20.72 | $67,270.05 |
DisclosureSEC source: 0001209191-16-153415 · doc4.xml · nonDerivative · entry 1 Wasman Jane · CIK 0001352455 · President, Intl and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,774 F1 · shares: Sales pursuant to a 10b5-1 plan. These sales are primarily intended to cover the tax liability resulting from restricted stock vesting. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $20.30 to $21.20 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 16:18 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 3,750 | $20.78 | $77,926.88 |
DisclosureSEC source: 0001209191-16-144914 · doc4.xml · nonDerivative · entry 1 Wasman Jane · CIK 0001352455 · President, Intl and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,021 F1 · shares: Sales pursuant to a 10b5-1 plan. These sales are primarily intended to cover the tax liability resulting from restricted stock vesting. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $20.6700 to $20.9121 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 23, 2016 Filed Sep 27, 2016 08:01 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 500 | $0.00 Strike: $8.50 | $0.00 |
DisclosureSEC source: 0001209191-16-142858 · doc4.xml · derivative · entry 3 Wasman Jane · CIK 0001352455 · President, Intl and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500 shares Expires 2016-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2016 on the expiration date reported within Table II unless exercised. F2 · derivative.exercise_date: The shares subject to these options vested in installments and were fully vested on September 25, 2010. Read SEC document |
| September 23, 2016 Filed Sep 27, 2016 08:01 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 500 | $27.32 | $13,660.30 |
DisclosureSEC source: 0001209191-16-142858 · doc4.xml · nonDerivative · entry 2 Wasman Jane · CIK 0001352455 · President, Intl and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,771 F1 · shares: Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2016 on the expiration date reported within Table II unless exercised. Read SEC document |
| September 23, 2016 Filed Sep 27, 2016 08:01 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Exercise / conversionCommon Stock | 500 | $8.50 | $4,250.00 |
DisclosureSEC source: 0001209191-16-142858 · doc4.xml · nonDerivative · entry 1 Wasman Jane · CIK 0001352455 · President, Intl and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,271 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2016 on the expiration date reported within Table II unless exercised. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.